Cryoinjury enhancement of breast cancer cells by use of a molecular adjuvant (TNF-ALPHA)

Bumsoo Han; Matthew D. Egberg; Pung P. Haung; David J. Swanlund; John C. Bischof

doi:10.1115/imece2004-61593

Cryoinjury enhancement of breast cancer cells by use of a molecular adjuvant (TNF-ALPHA)

Bumsoo Han, Matthew D. Egberg, Pung P. Haung, David J. Swanlund, John C. Bischof

Research output: Contribution to journal › Conference article › peer-review

Abstract

Cryoinjury of human breast cancer cells (MCF7) in engineered tissue equivalents and the enhancement of the cryoinjury by use of a molecular adjuvant (tumor necrosis factor alpha, TNF-α) was studied. Tissue equivalents (TEs) were constructed by seeding MCF7 cells in collagen solutions at the concentration of 100,000 cells/ml. After cultured in vitro for 2 days, the TEs were exposed with 100ng/ml TNF-α and cultured for 24 hours, and then underwent a single freeze-thaw cycle by a cryosurgery simulator. With the concentration and duration of TNF-α treatment studied, no apoptotic or necrotic cell death was observed by the administration of TNF-α only. After a freeze/thaw, MCF7 cells within the frozen region of the TEs were significantly injured immediately (i.e. ≤ 20% survival), but gradually repopulated and reached approximately 80% survival in Day3 without TNF-α pre-treatment. MCF7 with TNF-α pre-treatment showed the slight enhancement of immediate injury in the frozen region (i.e. ≤ 10% survival), and the repopulation was significantly inhibited so the viability remained below 40% even in Day 3. These results imply that TNF-α can be a potent adjuvant for cryosurgery.

Original language	English (US)
Article number	IMECE2004-61593
Pages (from-to)	93-94
Number of pages	2
Journal	Advances in Bioengineering, BED
DOIs	https://doi.org/10.1115/imece2004-61593
State	Published - 2004
Externally published	Yes
Event	2004 ASME International Mechanical Engineering Congress and Exposition, IMECE - Anaheim, CA, United States Duration: Nov 13 2004 → Nov 19 2004

ASJC Scopus subject areas

General Engineering

Online availability

10.1115/imece2004-61593

Library availability

Discover UIUC Full Text

Cite this

@article{331bfcb47b394aee9efa3da3b301cb5e,

title = "Cryoinjury enhancement of breast cancer cells by use of a molecular adjuvant (TNF-ALPHA)",

abstract = "Cryoinjury of human breast cancer cells (MCF7) in engineered tissue equivalents and the enhancement of the cryoinjury by use of a molecular adjuvant (tumor necrosis factor alpha, TNF-α) was studied. Tissue equivalents (TEs) were constructed by seeding MCF7 cells in collagen solutions at the concentration of 100,000 cells/ml. After cultured in vitro for 2 days, the TEs were exposed with 100ng/ml TNF-α and cultured for 24 hours, and then underwent a single freeze-thaw cycle by a cryosurgery simulator. With the concentration and duration of TNF-α treatment studied, no apoptotic or necrotic cell death was observed by the administration of TNF-α only. After a freeze/thaw, MCF7 cells within the frozen region of the TEs were significantly injured immediately (i.e. ≤ 20% survival), but gradually repopulated and reached approximately 80% survival in Day3 without TNF-α pre-treatment. MCF7 with TNF-α pre-treatment showed the slight enhancement of immediate injury in the frozen region (i.e. ≤ 10% survival), and the repopulation was significantly inhibited so the viability remained below 40% even in Day 3. These results imply that TNF-α can be a potent adjuvant for cryosurgery.",

author = "Bumsoo Han and Egberg, {Matthew D.} and Haung, {Pung P.} and Swanlund, {David J.} and Bischof, {John C.}",

year = "2004",

doi = "10.1115/imece2004-61593",

language = "English (US)",

pages = "93--94",

journal = "Advances in Bioengineering, BED",

issn = "0360-9960",

note = "2004 ASME International Mechanical Engineering Congress and Exposition, IMECE ; Conference date: 13-11-2004 Through 19-11-2004",

}

TY - JOUR

T1 - Cryoinjury enhancement of breast cancer cells by use of a molecular adjuvant (TNF-ALPHA)

AU - Han, Bumsoo

AU - Egberg, Matthew D.

AU - Haung, Pung P.

AU - Swanlund, David J.

AU - Bischof, John C.

PY - 2004

Y1 - 2004

N2 - Cryoinjury of human breast cancer cells (MCF7) in engineered tissue equivalents and the enhancement of the cryoinjury by use of a molecular adjuvant (tumor necrosis factor alpha, TNF-α) was studied. Tissue equivalents (TEs) were constructed by seeding MCF7 cells in collagen solutions at the concentration of 100,000 cells/ml. After cultured in vitro for 2 days, the TEs were exposed with 100ng/ml TNF-α and cultured for 24 hours, and then underwent a single freeze-thaw cycle by a cryosurgery simulator. With the concentration and duration of TNF-α treatment studied, no apoptotic or necrotic cell death was observed by the administration of TNF-α only. After a freeze/thaw, MCF7 cells within the frozen region of the TEs were significantly injured immediately (i.e. ≤ 20% survival), but gradually repopulated and reached approximately 80% survival in Day3 without TNF-α pre-treatment. MCF7 with TNF-α pre-treatment showed the slight enhancement of immediate injury in the frozen region (i.e. ≤ 10% survival), and the repopulation was significantly inhibited so the viability remained below 40% even in Day 3. These results imply that TNF-α can be a potent adjuvant for cryosurgery.

AB - Cryoinjury of human breast cancer cells (MCF7) in engineered tissue equivalents and the enhancement of the cryoinjury by use of a molecular adjuvant (tumor necrosis factor alpha, TNF-α) was studied. Tissue equivalents (TEs) were constructed by seeding MCF7 cells in collagen solutions at the concentration of 100,000 cells/ml. After cultured in vitro for 2 days, the TEs were exposed with 100ng/ml TNF-α and cultured for 24 hours, and then underwent a single freeze-thaw cycle by a cryosurgery simulator. With the concentration and duration of TNF-α treatment studied, no apoptotic or necrotic cell death was observed by the administration of TNF-α only. After a freeze/thaw, MCF7 cells within the frozen region of the TEs were significantly injured immediately (i.e. ≤ 20% survival), but gradually repopulated and reached approximately 80% survival in Day3 without TNF-α pre-treatment. MCF7 with TNF-α pre-treatment showed the slight enhancement of immediate injury in the frozen region (i.e. ≤ 10% survival), and the repopulation was significantly inhibited so the viability remained below 40% even in Day 3. These results imply that TNF-α can be a potent adjuvant for cryosurgery.

UR - http://www.scopus.com/inward/record.url?scp=20644460792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20644460792&partnerID=8YFLogxK

U2 - 10.1115/imece2004-61593

DO - 10.1115/imece2004-61593

M3 - Conference article

AN - SCOPUS:20644460792

SN - 0360-9960

SP - 93

EP - 94

JO - Advances in Bioengineering, BED

JF - Advances in Bioengineering, BED

M1 - IMECE2004-61593

T2 - 2004 ASME International Mechanical Engineering Congress and Exposition, IMECE

Y2 - 13 November 2004 through 19 November 2004

ER -

Cryoinjury enhancement of breast cancer cells by use of a molecular adjuvant (TNF-ALPHA)

Abstract

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this